Unique pharmacological actions of atypical neuroleptic quetiapine: Possible role in cell cycle/fate control

Translational Psychiatry

Volumn 3, Issue , 2013, Pages

  Kondo, M A ^a   Tajinda, K ^a,b   Colantuoni, C ^a,c   Hiyama, H ^a,b   Seshadri, S ^a   Huang, B ^a   Pou, S ^a   Furukori, K ^a   Hookway, C ^a   Jaaro Peled, H ^a   Kano, S I ^a   Matsuoka, N ^b   Harada, K ^b   Ni, K ^b   Pevsner, J ^a,d,e   Sawa, A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ASTELLAS PHARMA INC   (Japan)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d KENNEDY KRIEGER INSTITUTE   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Cell cycle; Gene expression; Mood disorders; Neuroleptics; Quetiapine; Schizophrenia

Indexed keywords

CELL DIVISION CYCLE AND APOPTOSIS REGULATOR 1; CHEMOKINE LIGAND 12; CHLORIDE CHANNEL 5; CYCLIN DEPENDENT KINASE INHIBITOR 1A; DNA J C3 PROTEIN; DNA TOPOISOMERASE; FOCAL ADHESION KINASE 1; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; HALOPERIDOL; HEPATOMA DERIVED GROWTH FACTOR; LEUKEMIA INHIBITORY FACTOR RECEPTOR; NUCLEAR RNA EXPORT FACTOR 7; ODD SKIPPED RELATED 1; PIWI LIKE HOMOLOG 2; POLYMERASE III POLYPEPTIDE K; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE ALPHA; PROTEIN; PROTEIN P21; QUETIAPINE; SID1 PROTEIN; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1A4; SPERMATOGENESIS ASSOCIATED 19; TETRATRICOPEPTIDE REPEAT 39B; TUMOR NECROSIS FACTOR RECEPTOR 25; UBIQUITIN SPECIFIC PEPTIDASE 2; UNCLASSIFIED DRUG; DIBENZOTHIAZEPINE DERIVATIVE; METHAMPHETAMINE; NEUROLEPTIC AGENT; P21 ACTIVATED KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CELL CYCLE REGULATION; CELL FATE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG MEGADOSE; FRONTAL CORTEX; GENE EXPRESSION; HOMEOSTASIS; IN SITU HYBRIDIZATION; MICROARRAY ANALYSIS; MOUSE; NEURAL STEM CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; OLIGODENDROGLIA; RAT; REAL TIME POLYMERASE CHAIN REACTION; ANALYSIS OF VARIANCE; ANIMAL; CELL CYCLE; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECT; FRONTAL LOBE; GENETICS; MALE; METABOLISM; NERVE CELL; PRINCIPAL COMPONENT ANALYSIS; SCHIZOPHRENIA; SPRAGUE DAWLEY RAT;

ANALYSIS OF VARIANCE; ANIMALS; ANTIPSYCHOTIC AGENTS; ASTROCYTES; CELL CYCLE; DIBENZOTHIAZEPINES; DISEASE MODELS, ANIMAL; FRONTAL LOBE; GENE EXPRESSION; HALOPERIDOL; IN SITU HYBRIDIZATION; MALE; METHAMPHETAMINE; MICE; NEURONS; OLIGODENDROGLIA; P21-ACTIVATED KINASES; PRINCIPAL COMPONENT ANALYSIS; RATS; RATS, SPRAGUE-DAWLEY; REAL-TIME POLYMERASE CHAIN REACTION; SCHIZOPHRENIA;

EID: 84878659252     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2013.19     Document Type: Article

References (60)

1. Fribourg M, Moreno JL, Holloway T, Provasi D, Baki L, Mahajan R et al. Decoding the signaling of a GPCR heteromeric complex reveals a unifying mechanism of action of antipsychotic drugs. Cell 2011; 147: 1011-1023.
2. Kondo M, Sawa A. Anti-/propsychotic drug signaling via heteromeric GPCRs -a balancing act? Cell 2011; 147: 964-965.
3. Lehmann HE, Hanrahan GE. Chlorpromazine; new inhibiting agent for psychomotor excitement and manic states. AMA Arch Neurol Psychiatry 1954; 71: 227-237.
4. Carlsson A, Lindqvist M. Effect of chlorpromazine or haloperidol on formation of 3methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol (Copenh) 1963; 20: 140-144.
5. Seeman P, Lee T. Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 1975; 188: 1217-1219.
6. Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976; 192: 481-483.
7. Purdon SE, Malla A, Labelle A, Lit W. Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J Psychiatry Neurosci 2001; 26: 137-149. (Pubitemid 32373127)
8. Woo TUW, Zimmet SV, Wojcik JD, Canuso CM, Green AI. Treatment of schizophrenia. In: Schatzberg AF, Nemeroff CB (eds). The American Psychiatric Publishing Textbook of Psychopharmacology. 4th edn American Psychiatric Publishers: Washington, DC, USA, 2009. pp 1135-1170.
9. Baune BT, Caliskan S, Todder D. Effects of adjunctive antidepressant therapy with quetiapine on clinical outcome, quality of sleep and daytime motor activity in patients with treatment-resistant depression. Hum Psychopharmacol 2007; 22: 1-9. (Pubitemid 46178772)
10. Bowden CL, Grunze H, Mullen J, Brecher M, Paulsson B, Jones M et al. A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry 2005; 66: 111-121.
11. McIntyre RS, Konarski JZ, Jones M, Paulsson B. Quetiapine in the treatment of acute bipolar mania: efficacy across a broad range of symptoms. J Affect Disord 2007; 100(Suppl 1): S5-S14. (Pubitemid 46818457)
12. McIntyre RS, Soczynska JK, Woldeyohannes HO, Alsuwaidan M, Konarski JZ. A preclinical and clinical rationale for quetiapine in mood syndromes. Expert Opin Pharmacother 2007; 8: 1211-1219. (Pubitemid 47034411)
13. Mohr N, Vythilingum B, Emsley RA, Stein DJ. Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder. Int Clin Psychopharmacol 2002; 17: 37-40. (Pubitemid 34056524)
14. Nemeroff CB, Kinkead B, Goldstein J. Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing. J Clin Psychiatry 2002; 63(Suppl 13): 5-11. (Pubitemid 35471364)
15. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 2000; 68: 29-39.
16. Richtand NM, Welge JA, Logue AD, Keck Jr PE, Strakowski SM, McNamara RK. Dopamine and serotonin receptor binding and antipsychotic efficacy. Neuropsychopharmacology 2007; 32: 1715-1726. (Pubitemid 47076385)
17. Shobo M, Kondo Y, Yamada H, Mihara T, Yamamoto N, Katsuoka M et al. Norzotepine, a major metabolite of zotepine, exerts atypical antipsychotic-like and antidepressant-like actions through its potent inhibition of norepinephrine reuptake. J Pharmacol Exp Ther 2010; 333: 772-781.
18. Wu Z, Irizarry RA, Gentleman R, Martinez-Murillo F, Spencer F. A model-based background adjustment for oligonucleotide expression arrays. J Am Statist Assoc 2004; 99: 909-917. (Pubitemid 39665934)
19. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545-15550. (Pubitemid 41528093)
20. Blackshaw S, Snyder SH. Developmental expression pattern of phototransduction components in mammalian pineal implies a light-sensing function. J Neurosci 1997; 17: 8074-8082. (Pubitemid 27461032)
21. Ozeki Y, Pickard BS, Kano S, Malloy MP, Zeledon M, Sun DQ et al. A novel balanced chromosomal translocation found in subjects with schizophrenia and schizotypal personality disorder: altered L-serine level associated with disruption of PSAT1 gene expression. Neurosci Res 2011; 69: 154-160.
22. Seshadri S, Kamiya A, Yokota Y, Prikulis I, Kano S, Hayashi-Takagi A et al. Disrupted-inschizophrenia-1 expression is regulated by beta-site amyloid precursor protein cleaving enzyme-1-neuregulin cascade. Proc Natl Acad Sci USA 2010; 107: 5622-5627.
23. Sawa A, Khan AA, Hester LD, Snyder SH. Glyceraldehyde-3-phosphate dehydrogenase: nuclear translocation participates in neuronal and nonneuronal cell death. Proc Natl Acad Sci USA 1997; 94: 11669-11674. (Pubitemid 27451056)
24. Cutler AJ, Goldstein JM, Tumas JA. Dosing and switching strategies for quetiapine fumarate. Clin Ther 2002; 24: 209-222. (Pubitemid 34208416)
25. Abbas T, Dutta A. P21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 2009; 9: 400-414.
26. Nagy Z. Cell cycle regulatory failure in neurones: causes and consequences. Neurobiol Aging 2000; 21: 761-769.
27. Herrup K, Yang Y. Cell cycle regulation in the postmitotic neuron: oxymoron or new biology? Nat Rev Neurosci 2007; 8: 368-378. (Pubitemid 46652467)
28. Benes FM, Lim B, Subburaju S. Site-specific regulation of cell cycle and DNA repair in postmitotic GABA cells in schizophrenic versus bipolars. Proc Natl Acad Sci USA 2009; 106: 11731-11736.
29. Bi X, Yan B, Fang S, Yang Y, He J, Li XM et al. Quetiapine regulates neurogenesis in ischemic mice by inhibiting NF-kappaB p65/p50 expression. Neurol Res 2009; 31: 159-166.
30. He J, Luo H, Yan B, Yu Y, Wang H, Wei Z et al. Beneficial effects of quetiapine in a transgenic mouse model of Alzheimer's disease. Neurobiol Aging 2009; 30: 1205-1216.
31. Bian Q, Kato T, Monji A, Hashioka S, Mizoguchi Y, Horikawa H et al. The effect of atypical antipsychotics, perospirone, ziprasidone and quetiapine on microglial activation induced by interferon-gamma. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 42-48.
32. Luo C, Xu H, Li XM. Quetiapine reverses the suppression of hippocampal neurogenesis caused by repeated restraint stress. Brain Res 2005; 1063: 32-39. (Pubitemid 41628205)
33. Tanibuchi Y, Fujita Y, Kohno M, Ishima T, Takatsu Y, Iyo M et al. Effects of quetiapine on phencyclidine-induced cognitive deficits in mice: a possible role of alpha1-adrenoceptors. Eur Neuropsychopharmacol 2009; 19: 861-867.
34. Wang L, Lockstone HE, Guest PC, Levin Y, Palotas A, Pietsch S et al. Expression profiling of fibroblasts identifies cell cycle abnormalities in schizophrenia. J Proteome Res 2010; 9: 521-527.
35. Feron F, Perry C, Hirning MH, McGrath J, Mackay-Sim A. Altered adhesion, proliferation and death in neural cultures from adults with schizophrenia. Schizophr Res 1999; 40: 211-218.
36. McCurdy RD, Feron F, Perry C, Chant DC, McLean D, Matigian N et al. Cell cycle alterations in biopsied olfactory neuroepithelium in schizophrenia and bipolar I disorder using cell culture and gene expression analyses. Schizophr Res 2006; 82: 163-173. (Pubitemid 43290680)
37. Fan Y, Abrahamsen G, McGrath JJ, Mackay-Sim A. Altered cell cycle dynamics in schizophrenia. Biol Psychiatry 2012; 71: 129-135.
38. Kerns D, Vong GS, Barley K, Dracheva S, Katsel P, Casaccia P et al. Gene expression abnormalities and oligodendrocyte deficits in the internal capsule in schizophrenia. Schizophr Res 2010; 120: 150-158.
39. Lucassen PJ, Stumpel MW, Wang Q, Aronica E. Decreased numbers of progenitor cells but no response to antidepressant drugs in the hippocampus of elderly depressed patients. Neuropharmacology 2010; 58: 940-949.
40. Golzio C, Willer J, Talkowski ME, Oh EC, Taniguchi Y, Jacquemont S et al. KCTD13 is a major driver of mirrored neuroanatomical phenotypes of the 16p11.2 copy number variant. Nature 2012; 485: 363-367.
41. Brandon NJ, Sawa A. Linking neurodevelopmental and synaptic theories of mental illness through DISC1. Nat Rev Neurosci 2011; 12: 707-722.
42. Valvezan AJ, Klein PS. GSK-3 and Wnt signaling in neurogenesis and bipolar disorder. Front Mol Neurosci 2012; 5: 1.
43. Voleti B, Duman RS. The roles of neurotrophic factor and Wnt signaling in depression. Clin Pharmacol Ther 2012; 91: 333-338.
44. Xiao L, Xu H, Zhang Y, Wei Z, He J, Jiang W et al. Quetiapine facilitates oligodendrocyte development and prevents mice from myelin breakdown and behavioral changes. Mol Psychiatry 2008; 13: 697-708. (Pubitemid 351861531)
45. Xu H, Yang HJ, McConomy B, Browning R, Li XM. Behavioral and neurobiological changes in C57BL/6 mouse exposed to cuprizone: effects of antipsychotics. Front Behav Neurosci 2010; 4: 8.
46. Zhang Y, Xu H, Jiang W, Xiao L, Yan B, He J et al. Quetiapine alleviates the cuprizoneinduced white matter pathology in the brain of C57BL/6 mouse. Schizophr Res 2008; 106: 182-191.
47. Katsel P, Davis KL, Li C, Tan W, Greenstein E, Kleiner Hoffman LB et al. Abnormal indices of cell cycle activity in schizophrenia and their potential association with oligodendrocytes. Neuropsychopharmacology 2008; 33: 2993-3009.
48. Tkachev D, Mimmack ML, Ryan MM, Wayland M, Freeman T, Jones PB et al. Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet 2003; 362: 798-805. (Pubitemid 37093922)
49. Sim K, Yang GL, Loh D, Poon LY, Sitoh YY, Verma S et al. White matter abnormalities and neurocognitive deficits associated with the passivity phenomenon in schizophrenia: a diffusion tensor imaging study. Psychiatry Res 2009; 172: 121-127.
50. Cheung V, Cheung C, McAlonan GM, Deng Y, Wong JG, Yip L et al. A diffusion tensor imaging study of structural dysconnectivity in never-medicated, first-episode schizophrenia. Psychol Med 2008; 38: 877-885. (Pubitemid 351684593)
51. Woodward ND, Rogers B, Heckers S. Functional resting-state networks are differentially affected in schizophrenia. Schizophr Res 2011; 130: 86-93.
52. Katsel P, Tan W, Abazyan B, Davis KL, Ross C, Pletnikov MV et al. Expression of mutant human DISC1 in mice supports abnormalities in differentiation of oligodendrocytes. Schizophr Res 2011; 130: 238-249.
53. Yoshizawa T, Yamagishi Y, Koseki N, Goto J, Yoshida H, Shibasaki F et al. Cell cycle arrest enhances the in vitro cellular toxicity of the truncated Machado-Joseph disease gene product with an expanded polyglutamine stretch. Hum Mol Genet 2000; 9: 69-78. (Pubitemid 30145290)
54. Jurk D, Wang C, Miwa S, Maddick M, Korolchuk V, Tsolou A et al. Postmitotic neurons develop a p21-dependent senescence-like phenotype driven by a DNA damage response. Aging Cell 2012; 11: 996-1004.
55. Harms C, Albrecht K, Harms U, Seidel K, Hauck L, Baldinger T et al. Phosphatidylinositol 3-Akt-kinase-dependent phosphorylation of p21(Waf1/Cip1) as a novel mechanism of neuroprotection by glucocorticoids. J Neurosci 2007; 27: 4562-4571. (Pubitemid 46663587)
56. Covington HE III, Lobo MK, Maze I, Vialou V, Hyman JM, Zaman S et al. Antidepressant effect of optogenetic stimulation of the medial prefrontal cortex. J Neurosci 2010; 30: 16082-16090.
57. Deng C, Zhang P, Harper JW, Elledge SJ, Leder P. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 1995; 82: 675-684.
58. Gonzalez-Cabrera PJ, Shi T, Yun J, McCune DF, Rorabaugh BR, Perez DM. Differential regulation of the cell cycle by alpha1-adrenergic receptor subtypes. Endocrinology 2004; 145: 5157-5167. (Pubitemid 39551137)
59. Sabatini DM, Erdjument-Bromage H, Lui M, Tempst P, Snyder SH. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 1994; 78: 35-43. (Pubitemid 24228298)
60. Brown EJ, Albers MW, Shin TB, Ichikawa K, Keith CT, Lane WS et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 1994; 369: 756-758.